Transthyretin Mediated Amyloidosis (ATTR) Completed Phase 2 Trials for Revusiran (DB16309)

Also known as: Transthyretin-Mediated Amyloidosis / Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) / Amyloidogenic Transthyretin (ATTR) Amyloidosis / Transthyretin (TTR)-Mediated Amyloidosis / Amyloidosis in Transthyretin (TTR) / Amyloid Transthyretin (ATTR) Amyloidosis / ATTR Amyloidosis

IndicationStatusPhase
DBCOND0047425 (Transthyretin Mediated Amyloidosis (ATTR))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02595983The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver TransplantTreatment